Catalent to Acquire Gene Therapy Leader Paragon Bioservices, Inc. for $1.2 Billion

34

SOMERSET, N.J. & BALTIMORE–(BUSINESS WIRE)–Catalent, Inc. (NYSE:CTLT), the leading global diversified provider of advanced delivery technologies and development solutions for drugs, biologics and consumer health products, and Paragon Bioservices, Inc., a leading viral vector development and manufacturing partner for gene therapies, today announced they have entered into a definitive agreement under which Catalent will acquire Paragon for $1.2 billion. “Paragon’s unparalleled expertise in the http://www.businesswire.com/news/home/20190415005197/en/Catalent-Acquire-Gene-Therapy-Leader-Paragon-Bioservices/?feedref=JjAwJuNHiystnCoBq_hl-WBlLQO14j4QZPTyX5CYOnwC4VjN53jumZRlnzhBoBxGrCOi9QzgjCezTS3Nw_X6kJUrpSBm-Hav1w-UkdSlG3ltkRSnqzf6ourQGu_UA28CzZCGORvG0LE20YOvo49uqw==